Nebivolol Zentiva (Nebivolol)

Nebivolol blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractility. At the same time it stimulates endothelial nitric‑oxide release, causing vasodilation and lowering peripheral resistance, which together contribute to a decrease in arterial pressure.

The specific dose of Nebivolol Zentiva is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any relevant comorbidities. Dosage adjustments are made according to individual therapeutic needs.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is distinguished by its high β1‑selectivity and additional nitric‑oxide‑mediated vasodilatory effect, which may result in fewer metabolic side effects compared with non‑selective beta‑blockers. Clinicians often consider it when a patient requires both heart‑rate reduction and improved peripheral vasodilation.

Nebivolol Zentiva tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Do not store in extreme heat or humidity to maintain product stability.

Nebivolol Zentiva is taken orally, usually once daily with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include severe bradycardia, symptomatic hypotension, and bronchospasm, especially in patients with underlying respiratory disease. Prompt medical attention is required if these events occur, as they can be life‑threatening.

Nebivolol Zentiva is contraindicated in patients with known hypersensitivity to nebivolol, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and individuals with uncompensated heart failure or cardiogenic shock.